Company
Founded on March 10, 2025, Beijing Lisen Ruike Health Technology Co., Ltd. is a health-tech enterprise with equity structure comprising Lisen Technology Co., Ltd. (Hong Kong, China) (50%), Jiataizecheng (Beijing) Medical Technology Co., Ltd. (33.3%), and natural shareholder Lu Bingli (16.67%). It plans to relocate its Beijing operations to Shenzhen, designating the Shenzhen branch as the R&D, supply chain, and business headquarters, while the Hong Kong entity serves as an international financing platform and overseas market hub.
Specializing in intelligent wearable medical health devices, the company offers an integrated solution of "AI algorithm + cloud-based health management + hardware monitoring" for full-age health management and chronic disease monitoring (e.g., diabetes, Parkinson's syndrome). Its products have completed technical verification in the UK and clinical testing in Thailand, currently in the sample stage, with mass production scheduled for August 2025 to supply Japanese and Fujian clients. The 2025 target revenue is approximately $300,000.
Led by Dr. Lu Bingli, a former Professor at the Hamlyn Centre for Surgery and Cancer, Imperial College London, the team holds strong technical credentials, including a Thai patent and support from European foundations. With pending patent applications in Shenzhen, the company has secured意向订单 (intentional orders) from hospitals and healthcare groups in Thailand, Japan, and Fujian, planning an angel round financing of $3-5 million via its Hong Kong parent by late 2025.
